Remove BioTech Remove Health Policy Remove Life Science Remove Telehealth
article thumbnail

Value-Based Health Care Needs All Stakeholders at the Table – Especially the Patient

Health Populi

The coolest thing in health policy in the 21st century!! ” Amitabh Chandra gave the opening context-setting talk about the effects of health care cost-sharing on patients-as-consumers. Kavita Patel to assert in the first panel of the day that, “2713 is my favorite number.”

article thumbnail

The Healthcare and Macro-Economic Impacts of Living with Endemic COVID – Listening to Fitch

Health Populi

The last point on “new technologies” begs the question, “who” will fund innovation in health care as we emerge from the pandemic with national economics growing back at different paces, and employment in a very different context than pre-pandemic.

BioTech 270
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

A Public Health Wake-Up Call: Reading Between the Lines in IQVIA’s 2023 Use of Medicines Report

Health Populi

First, we look at the macro picture on health services utilization comparing the end of 2022 with pre-COVID-19 levels. we see an over-indexing of office, institutional and telehealth visits (at 108) and a 104 gauge on new prescriptions.

article thumbnail

Americans Across Political Party Worry About Prescription Drug Prices – Especially to Deal with COVID-19

Health Populi

In today’s pharma/biotech market, the “specialty” label is given to many therapies: for products addressing rare diseases, risk-management, and above all, high cost drugs. The phrase “specialty drugs” originated in the 1970s in the advent of injectable and infusion therapies. Other countries outside of the U.S.

BioTech 191